Hospital-Initiated Smoking Cessation Among Patients Admitted with Behavioral Health Conditions.
hospitals
mental health
mood disorders
schizophrenia spectrum and other psychotic disorders
smoking cessation
substance-related disorders
Journal
Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
08
09
2023
accepted:
22
01
2024
medline:
8
2
2024
pubmed:
8
2
2024
entrez:
7
2
2024
Statut:
aheadofprint
Résumé
Smoking rates among people living with behavioral health conditions (BHC) range from 30 to 65% and are 2-4 times higher than rates found in the general population. Starting tobacco treatment during a hospital stay is effective for smoking cessation, but little is known regarding treatment response among inpatients with BHC. This study pooled data across multiple clinical trials to determine the relative success in quitting among participants with BHC compared to other study participants. Adults who smoke (≥ 18 years old) from five hospital-based smoking cessation randomized clinical trials. A retrospective analysis using data from the electronic health record to identify participants with primary diagnoses related to BHC. Recruitment and data analysis were conducted from 2011 to 2016. We used propensity score matching to pair patients with BHC to those with similar characteristics and logistic regression to determine differences between groups. The main outcome was self-reported 30-day abstinence 6 months post-discharge. Of 6612 participants, 798 patients had a BHC-related primary diagnosis. The matched sample included 642 pairs. Nearly 1 in 3 reported using tobacco medications after hospitalization, with no significant difference between patients with and without BHC (29.3% vs. 31.5%; OR (95% CI) = 0.90 (0.71, 1.14), p = 0.40). Nearly 1 in 5 patients with BHC reported abstinence at 6 months; however, their odds of abstinence were 30% lower than among people without BHC (OR (95% CI) = 0.70 (0.53,0.92), p = 0.01). When offered tobacco treatment, hospitalized patients with BHC were as likely as people without BHC to accept and engage in treatment. However, patients with BHC were less likely to report abstinence compared to those without BHC. Hospitals are a feasible and promising venue for tobacco treatment among inpatients with BHC. More studies are needed to identify treatment approaches that help people with BHC achieve long-term abstinence.
Sections du résumé
BACKGROUND
BACKGROUND
Smoking rates among people living with behavioral health conditions (BHC) range from 30 to 65% and are 2-4 times higher than rates found in the general population. Starting tobacco treatment during a hospital stay is effective for smoking cessation, but little is known regarding treatment response among inpatients with BHC.
OBJECTIVE
OBJECTIVE
This study pooled data across multiple clinical trials to determine the relative success in quitting among participants with BHC compared to other study participants.
PARTICIPANTS
METHODS
Adults who smoke (≥ 18 years old) from five hospital-based smoking cessation randomized clinical trials.
DESIGN
METHODS
A retrospective analysis using data from the electronic health record to identify participants with primary diagnoses related to BHC. Recruitment and data analysis were conducted from 2011 to 2016. We used propensity score matching to pair patients with BHC to those with similar characteristics and logistic regression to determine differences between groups.
MEASURES
METHODS
The main outcome was self-reported 30-day abstinence 6 months post-discharge.
RESULTS
RESULTS
Of 6612 participants, 798 patients had a BHC-related primary diagnosis. The matched sample included 642 pairs. Nearly 1 in 3 reported using tobacco medications after hospitalization, with no significant difference between patients with and without BHC (29.3% vs. 31.5%; OR (95% CI) = 0.90 (0.71, 1.14), p = 0.40). Nearly 1 in 5 patients with BHC reported abstinence at 6 months; however, their odds of abstinence were 30% lower than among people without BHC (OR (95% CI) = 0.70 (0.53,0.92), p = 0.01).
CONCLUSION
CONCLUSIONS
When offered tobacco treatment, hospitalized patients with BHC were as likely as people without BHC to accept and engage in treatment. However, patients with BHC were less likely to report abstinence compared to those without BHC. Hospitals are a feasible and promising venue for tobacco treatment among inpatients with BHC. More studies are needed to identify treatment approaches that help people with BHC achieve long-term abstinence.
Identifiants
pubmed: 38326585
doi: 10.1007/s11606-024-08646-5
pii: 10.1007/s11606-024-08646-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL105232
Pays : United States
Organisme : NHLBI NIH HHS
ID : RC1HL099668
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01HL105229
Pays : United States
Organisme : NIDA NIH HHS
ID : U01DA031515
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Society of General Internal Medicine.
Références
Peacock A, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018. 113(10):1905-1926.
doi: 10.1111/add.14234
pubmed: 29749059
Fornaro M, et al. The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis. Neurosci Biobehav Rev, 2022. 132:289-303.
doi: 10.1016/j.neubiorev.2021.11.039
pubmed: 34838527
Han B, et al. Trends in Prevalence of cigarette smoking among US adults with major depression or substance use disorders, 2006-2019. JAMA, 2022. 327(16):1566-1576.
doi: 10.1001/jama.2022.4790
pubmed: 35471512
pmcid: 9044114
Smith PH, et al. Cigarette smoking among those with mental disorders in the US population: 2012–2013 update. Tobacco Control, 2020. 29(1):29.
doi: 10.1136/tobaccocontrol-2018-054268
pubmed: 30377242
Weinberger AH, et al. Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002-2016. Tob Control, 2020. 29(1):74-80.
doi: 10.1136/tobaccocontrol-2018-054590
pubmed: 30952691
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res, 2005. 76(2-3):135-57.
doi: 10.1016/j.schres.2005.02.010
pubmed: 15949648
Korchia T, et al. Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. Prog Neuropsychopharmacol Biol Psychiatry, 2022. 114:110479.
doi: 10.1016/j.pnpbp.2021.110479
pubmed: 34826559
Tam J, Warner KE, Meza R. Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med, 2016. 51(6):958-966.
doi: 10.1016/j.amepre.2016.06.007
pubmed: 27522471
Richter KP, et al. Commitment and capacity for providing evidence-based tobacco treatment in US drug treatment facilities. Subst Abus, 2017. 38(1):35-39.
doi: 10.1080/08897077.2016.1265039
pubmed: 27897468
Owens PL, McDermott KW, and H. KC. Inpatient stays involving mental and substance use disorders. Agency for Healthcare Research and Quality. 2016;2019.
Rigotti NA, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev, 2012. 5(5):Cd001837.
pubmed: 22592676
Ylioja T, et al. Postdischarge smoking cessation in subgroups of hospitalized smokers: A latent class analysis. Subst Abus, 2017. 38(4):493-497.
doi: 10.1080/08897077.2017.1355870
pubmed: 28727541
pmcid: 6168063
Sanford, BT, et al. Tobacco treatment outcomes for hospital patients with and without mental health diagnoses. Front Psychiatry, 2022. 13: 853001.
doi: 10.3389/fpsyt.2022.853001
pubmed: 35722554
pmcid: 9199856
Prochaska JJ, et al. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health, 2014. 104(8): 1557-65.
doi: 10.2105/AJPH.2013.301403
pubmed: 23948001
pmcid: 4103208
Brown RA, et al. Sustained care smoking cessation intervention for individuals hospitalized for psychiatric disorders: The Helping HAND 3 randomized clinical trial. JAMA Psychiatry, 2021. 78(8): 839-847.
doi: 10.1001/jamapsychiatry.2021.0707
pubmed: 33950156
Riley WT, et al. Overview of the Consortium of Hospitals Advancing Research on Tobacco (CHART). Trials, 2012. 13:122.
doi: 10.1186/1745-6215-13-122
pubmed: 22852768
pmcid: 3479413
Richter KP, et al. Warm handoff versus fax referral for linking hospitalized smokers to quitlines. Am J Prev Med, 2016. 51(4): 587-96.
doi: 10.1016/j.amepre.2016.04.006
pubmed: 27647059
pmcid: 5031370
Sherman SE, et al. Smoking-cessation interventions for urban hospital patients: a randomized comparative effectiveness trial. Am J Prev Med, 2016. 51(4):566-77.
doi: 10.1016/j.amepre.2016.06.023
pubmed: 27647057
pmcid: 5089173
Fellows JL, et al. Referring hospitalized smokers to outpatient quit services: a randomized trial. Am J Prev Med, 2016. 51(4):609-19.
doi: 10.1016/j.amepre.2016.06.014
pubmed: 27647061
pmcid: 5031367
Kathleen FH, et al. Web-based intervention for transitioning smokers from inpatient to outpatient care: an RCT. Am J Prev Med, 2016. 51(4):620-9.
doi: 10.1016/j.amepre.2016.04.008
Cummins SE, et al. Helping hospitalized smokers: a factorial RCT of nicotine patches and counseling. Am J Prev Med, 2016. 51(4):p 578-86.
doi: 10.1016/j.amepre.2016.06.021
pubmed: 27647058
pmcid: 5031241
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Mental Health Annual Report: 2015–2020. Use of Mental Health Services: National Client-Level Data (Appendix E). Rockville, MD: Substance Abuse and Mental Health Services Administration, 2022
Yuan Y, Yung YF, Stokes ME. Propensity score methods for causal inference with the PSMATCH Procedure. 2017.
Rigotti NA, et al. A post-discharge smoking-cessation intervention for hospital patients: Helping Hand 2 Randomized Clinical Trial. Am J Prev Med, 2016. 51(4):597-608.
doi: 10.1016/j.amepre.2016.04.005
pubmed: 27647060
pmcid: 5031242
Anthenelli RM, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 2016. 387(10037):2507-20.
doi: 10.1016/S0140-6736(16)30272-0
pubmed: 27116918
Cinciripini PM, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety, 2022. 39(5):429-440.
doi: 10.1002/da.23259
pubmed: 35535436
pmcid: 9705120
Falcaro M, et al. Time trends in access to smoking cessation support for people with depression or severe mental illness: a cohort study in English primary care. BMJ Open, 2021. 11(12):e048341.
doi: 10.1136/bmjopen-2020-048341
pubmed: 34862277
pmcid: 8647398
Gilbody S, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry, 2019. 6(5):379-390.
doi: 10.1016/S2215-0366(19)30047-1
pubmed: 30975539
pmcid: 6546931
Evins AE, Cather C, Daumit GL. Smoking cessation in people with serious mental illness. Lancet Psychiatry, 2019.
Marynak K, et al. Tobacco cessation interventions and smoke-free policies in mental health and substance abuse treatment facilities - United States, 2016. MMWR Morb Mortal Wkly Rep, 2018. 67(18):519-523.
doi: 10.15585/mmwr.mm6718a3
pubmed: 29746451
pmcid: 5944973
American Psychiatric Association Presidential Report on the Assessment of Psychiatric Bed Needs in the United States. The Psychiatric Bed Crisis in the United States: Understanding the Problem and Moving Toward Solutions. Am J Psychiatry. 2022;179(8):586-588. https://doi.org/10.1176/appi.ajp.22179004 .
Dohnke B, et al. Do hospital treatments represent a 'teachable moment' for quitting smoking? A study from a stage-theoretical perspective. Psychol Health, 2012. 27(11): 1291-307.
doi: 10.1080/08870446.2012.672649
pubmed: 22472171